

# **Instructions for Use**

RealStar® HAV RT-PCR Kit 1.0

01/2017 EN

# RealStar® HAV RT-PCR Kit 1.0

#### For use with

m2000rt (Abbott Diagnostics)

Mx 3005P™ QPCR System (Stratagene)

VERSANT® kPCR Molecular System AD (Siemens Healthcare)

ABI Prism® 7500 SDS (Applied Biosystems)

Rotor-Gene® 6000 (Corbett Research)

Rotor-Gene® Q5/6 plex Platform (QIAGEN)

CFX96™ Real-Time PCR Detection System (Bio-Rad)

LightCycler® 480 Instrument II (Roche)

C€















altona Diagnostics GmbH • Mörkenstr. 12 • D-22767 Hamburg

## Content

1.	Intended Use	. 6
2.	Kit Components	. 6
3.	Storage	. 6
4.	Material and Devices required but not provided	. 7
5.	Background Information	. 8
6.	Product Description	. 9
6.1	Real-Time PCR Instruments	10
7.	Warnings and Precautions	11
8.	Procedure	12
8.1	Sample Preparation	12
8.2	Master Mix Setup	13
8.3	Reaction Setup	15
9.	Programming the Real-Time PCR Instrument	16
9.1	Settings	16
9.2	Fluorescence Detectors (Dyes)	16
9.3	Temperature Profile and Dye Acquisition	17
10.	Data Analysis	18
10.1	Validity of Diagnostic Test Runs	18
10.1.1	Valid Diagnostic Test Run	18
10.1.2	Invalid Diagnostic Test Run	18
10.2	Interpretation of Results	19
10.2.1	Qualitative Analysis	19

1.	Performance Evaluation	20
1.1	Analytical Sensitivity	20
1.2	Analytical Specificity	21
1.3	Precision	22
2.	Limitations	23
3.	Quality Control	24
4.	Technical Assistance	24
5.	Literature	24
6.	Trademarks and Disclaimers	25
7	Explanation of Symbols	26

#### 1. Intended Use

The RealStar® HAV RT-PCR Kit 1.0 is an *in vitro* diagnostic test, based on real-time PCR technology, for the detection of hepatitis A virus (HAV) specific RNA.

## 2. Kit Components

Lid Color	Component	Number of Vials	Volume [μl/Vial]
Blue	Master A	8	60
Purple	Master B	8	240
Green	Internal Control	1	1000
Red	Positive Control	1	625
White	Water (PCR grade)	1	500

## 3. Storage

- The RealStar® HAV RT-PCR Kit 1.0 is shipped on dry ice. The components of the kit should arrive frozen. If one or more components are not frozen upon receipt, or if tubes have been compromised during shipment, contact altona Diagnostics GmbH for assistance.
- All components should be stored between -25°C and -15°C upon arrival.
- Repeated thawing and freezing of Master reagents (more than twice) should be avoided, as this might affect the performance of the assay. The reagents should be frozen in aliquots, if they are to be used intermittently.
- Storage between +2°C and +8°C should not exceed a period of two hours.
- Protect Master A and Master B from light.

## 4. Material and Devices required but not provided

- Appropriate real-time PCR instrument (see chapter 6.1 Real-Time PCR Instruments)
- · Appropriate nucleic acid extraction system or kit
- · Desktop centrifuge with a rotor for 2 ml reaction tubes
- Centrifuge with a rotor for microtiter plates, if using 96 well reaction plates
- Vortex mixer
- Appropriate 96 well reaction plates or reaction tubes with corresponding (optical) closing material
- Pipettes (adjustable)
- Pipette tips with filters (disposable)
- · Powder-free gloves (disposable)

NOTE	
i	Please ensure that all instruments used have been installed, calibrated, checked and maintained according to the manufacturer's instructions and recommendations.
i	It is highly recommended to use the 72-well rotor with the appropriate 0.1 ml reaction tubes, if using the Rotor-Gene® 6000 (Corbett Research) or the Rotor-Gene® Q 5/6 plex (QIAGEN).

#### 5. Background Information

Hepatitis A virus (HAV) is the type species of the genus Hepatovirus within the family Picornaviridae. HAV is a small virus with a non-enveloped, icosahedral capsid approximately 27 nm in diameter. The viral genome is composed of linear, positive-sense RNA of about 7.500 bp in length.

The primary mode of HAV transmission is via human faeces. Being excreted in very high concentrations HAV is able to cause waterborne outbreaks as well as person-to-person spread.

HAV is found worldwide, but with widely varying epidemical patterns that largely reflect sanitation standards. The virus causes acute and generally self-limiting infections without significant long-term carrier status. Despite there are no serious long-term sequelae in patients who recover from hepatits A, severe outcomes are seen in patients with acute hepatitis A on a background of chronic hepatitis B virus or hepatitis C virus infection.

Vaccination for hepatitis A virus is not complicated by strain differences, despite significant levels of amino acid variation in the capsid proteins, as HAV exists as a single serotype worldwide.

#### NOTE



Due to the relatively fast molecular evolution of RNA viruses, there is an inherent risk for any RT-PCR based test system that accumulation of mutations over time may lead to false negative results.

#### 6. Product Description

The RealStar® HAV RT-PCR Kit 1.0 is an *in vitro* diagnostic test, based on real-time PCR technology, for the detection of hepatitis A virus (HAV) specific RNA. The assay includes a heterologous amplification system (Internal Control) to identify possible RT-PCR inhibition and to confirm the integrity of the reagents of the kit.

Real-time RT-PCR technology utilizes reverse-transcriptase (RT) reaction to convert RNA into complementary DNA (cDNA), polymerase chain reaction (PCR) for the amplification of specific target sequences and target specific probes for the detection of the amplified DNA. The probes are labelled with fluorescent reporter and quencher dyes.

Probes specific for HAV RNA are labelled with the fluorophore FAM™. The probe specific for the Internal Control (IC) is labelled with the fluorophore JOE™.

Using probes linked to distinguishable dyes enables the parallel detection of HAV specific RNA and the Internal Control in corresponding detector channels of the real-time PCR instrument.

The test consists of three processes in a single tube assay:

- Reverse transcription of target and Internal Control RNA to cDNA
- · PCR amplification of target and Internal Control cDNA
- Simultaneous detection of PCR amplicons by fluorescent dye labelled probes

The RealStar® HAV RT-PCR Kit 1.0 consists of:

- Two Master reagents (Master A and Master B)
- Internal Control (IC)
- · Positive Control
- PCR grade water

Master A and Master B contain all components (PCR buffer, reverse transcriptase, DNA polymerase, magnesium salt, primers and probes) to allow reverse transcription, PCR mediated amplification and target detection of HAV specific RNA and Internal Control in one reaction setup.

#### 6.1 Real-Time PCR Instruments

The RealStar® HAV RT-PCR Kit 1.0 was developed and validated to be used with the following real-time PCR instruments:

- m2000rt (Abbott Diagnostics)
- Mx 3005P™ QPCR System (Stratagene)
- VERSANT® kPCR Molecular System AD (Siemens Healthcare)
- ABI Prism® 7500 SDS (Applied Biosystems)
- Rotor-Gene® 6000 (Corbett Research)
- Rotor-Gene® Q5/6 plex Platform (QIAGEN)
- CFX96™ Real-Time PCR Detection System (Bio-Rad)
- LightCycler® 480 Instrument II (Roche)

#### 7. Warnings and Precautions

Read the Instructions for Use carefully before using the product.

- Before first use check the product and its components for:
  - Integrity
  - Completeness with respect to number, type and filling (see chapter 2. Kit Components)
  - Correct labelling
  - Frozenness upon arrival
- Use of this product is limited to personnel specially instructed and trained in the techniques of real-time PCR and *in vitro* diagnostic procedures.
- Specimens should always be treated as infectious and/or biohazardous in accordance with safe laboratory procedures.
- Wear protective disposable powder-free gloves, a laboratory coat and eye protection when handling specimens.
- Avoid microbial and nuclease (DNase/RNase) contamination of the specimens and the components of the kit.
- Always use DNase/RNase-free disposable pipette tips with aerosol barriers.
- Always wear protective disposable powder-free gloves when handling kit components.
- Use separated and segregated working areas for (i) sample preparation, (ii) reaction setup and (iii) amplification/detection activities. The workflow in the laboratory should proceed in unidirectional manner. Always wear disposable gloves in each area and change them before entering a different area.
- Dedicate supplies and equipment to the separate working areas and do not move them from one area to another.
- Store positive and/or potentially positive material separated from all other components of the kit.
- Do not open the reaction tubes/plates post amplification, to avoid contamination with amplicons.

- Additional controls may be tested according to guidelines or requirements of local, state and/or federal regulations or accrediting organizations.
- Do not autoclave reaction tubes after the PCR, since this will not degrade the amplified nucleic acid and will bear the risk to contaminate the laboratory area.
- Do not use components of the kit that have passed their expiration date.
- Discard sample and assay waste according to your local safety regulations.

#### 8. Procedure

#### 8.1 Sample Preparation

Extracted RNA is the starting material for the RealStar® HAV RT-PCR Kit 1.0.

The quality of the extracted RNA has a profound impact on the performance of the entire test system. It has to be ensured that the system used for nucleic acid extraction is compatible with real-time PCR technology. The following kits and systems are suitable for nucleic acid extraction:

- QIAamp® Viral RNA Mini Kit (QIAGEN)
- QIAsymphony® (QIAGEN)
- NucliSENS® easyMag® (bioMérieux)
- MagNA Pure 96 System (Roche)
- m2000sp (Abbott)
- Maxwell® 16IVD Instrument (Promega)
- VERSANT® kPCR Molecular System SP (Siemens Healthcare)

Alternative nucleic acid extraction systems and kits might also be appropriate. The suitability of the nucleic acid extraction procedure for use with RealStar® HAV RT-PCR Kit 1.0 has to be validated by the user.

If using a spin column based sample preparation procedure including washing buffers containing ethanol, it is highly recommended to perform an additional centrifugation step for 10 min at approximately 17000 x g (~ 13000 rpm), using a new collection tube, prior to the elution of the nucleic acid.

#### CAUTION



If your sample preparation system is using washing buffers containing ethanol, make sure to eliminate any traces of ethanol prior to elution of the nucleic acid. Ethanol is a strong inhibitor of real-time PCR.

#### **CAUTION**



The use of carrier RNA is crucial for extraction efficiency and stability of the extracted nucleic acid.

For additional information and technical support regarding pre-treatment and sample preparation please contact our Technical Support (see chapter 14. Technical Assistance).

## 8.2 Master Mix Setup

All reagents and samples should be thawed completely, mixed (by pipetting or gentle vortexing) and centrifuged briefly before use.

The RealStar® HAV RT-PCR Kit 1.0 contains a heterologous Internal Control (IC), which can either be used as a RT-PCR inhibition control or as a control of the sample preparation procedure (nucleic acid extraction) and as a RT-PCR inhibition control.

▶ If the IC is used as a RT-PCR inhibition control, but not as a control for the sample preparation procedure, set up the Master Mix according to the following pipetting scheme:

Number of Reactions (rxns)	1	12
Master A	5 µl	60 µl
Master B	20 µl	240 μΙ
Internal Control	2.5 µl	30 µl
Volume Master Mix	27.5 µl	330 µl

- ▶ If the IC is used as a control for the sample preparation procedure <u>and</u> as a RT-PCR inhibition control, add the IC during the nucleic acid extraction procedure.
- ▶ No matter which method/system is used for nucleic acid extraction, the IC must not be added directly to the specimen. The IC should always be added to the specimen/lysis buffer mixture. The volume of the IC which has to be added, always and only depends on the elution volume. It represents 10% of the elution volume. For instance, if the nucleic acid is going to be eluted in 60 µl of elution buffer or water, 6 µl of IC per sample must be added into the specimen/lysis buffer mixture.
- ▶ If the IC was added during the sample preparation procedure, set up the Master Mix according to the following pipetting scheme:

Number of Reactions (rxns)	1	12
Master A	5 µl	60 µl
Master B	20 μΙ	240 μΙ
Volume Master Mix	25 µl	300 μl

#### CAUTION



If the IC (Internal Control) was added during the sample preparation procedure, at least the negative control must include the IC.



No matter which method/system is used for nucleic acid extraction, never add the IC directly to the specimen.

### 8.3 Reaction Setup

- Pipette 25 μl of the Master Mix into each required well of an appropriate optical 96-well reaction plate or an appropriate optical reaction tube.
- ► Add 25 μl of the sample (eluate from the nucleic acid extraction) or 25 μl of the controls (Positive or Negative Control).

Reaction Setup		
Master Mix	25 μΙ	
Sample or Control	25 μΙ	
Total Volume	50 μl	

- ▶ Make sure that at least one Positive and one Negative Control is used per run.
- ► Thoroughly mix the samples and controls with the Master Mix by pipetting up and down.
- ► Close the 96-well reaction plate with appropriate lids or optical adhesive film and the reaction tubes with appropriate lids.
- ► Centrifuge the 96-well reaction plate in a centrifuge with a microtiter plate rotor for 30 seconds at approximately 1000 x g (~ 3000 rpm).

## 9. Programming the Real-Time PCR Instrument

For basic information regarding the setup and programming of the different real-time PCR instruments, please refer to the user manual of the respective instrument. For detailed programming instructions regarding the use of the RealStar® HAV RT-PCR Kit 1.0 on specific real-time PCR instruments please contact our Technical Support (see chapter 14. Technical Assistance).

## 9.1 Settings

▶ Define the following settings:

Settings		
Reaction Volume	50 μl	
Ramp Rate	Default	
Passive Reference	None	

## 9.2 Fluorescence Detectors (Dyes)

▶ Define the fluorescence detectors (dyes):

Target	Detector Name	Reporter	Quencher
HAV specific RNA	HAV	FAM™	(None)
Internal Control	IC	JOE™	(None)

## 9.3 Temperature Profile and Dye Acquisition

▶ Define the temperature profile and dye acquisition:

	Stage	Cycle Repeats	Acquisition	Temperature [°C]	Time [min:sec]
Reverse Transcription	Hold	1	-	50	10:00
Denaturation	Hold	1	-	95	10:00
	Amplification Cycling	45	-	95	00:15
Amplification			Yes	55	00:45
			-	72	00:15

## 10. Data Analysis

For basic information regarding data analysis on specific real-time PCR instruments, please refer to the user manual of the respective instrument.

For detailed instructions regarding the analysis of the data generated with the RealStar® HAV RT-PCR Kit 1.0 on different real-time PCR instruments please contact our Technical Support (see chapter 14. Technical Assistance).

#### 10.1 Validity of Diagnostic Test Runs

#### 10.1.1 Valid Diagnostic Test Run

For a valid diagnostic test run, the following control conditions must be met:

Control ID	Detection Channel	
Control ID	FAM™	JOE™
Positive Control	+	+/-*
Negative Control	-	+

<sup>\*</sup> The presence or absence of a signal in the JOE™ channel is not relevant for the validity of the test run.

## 10.1.2 Invalid Diagnostic Test Run

A diagnostic test run is **invalid**, (i) if the run has not been completed or (ii) if any of the control conditions for a **valid** diagnostic test run are not met.

In case of an **invalid** diagnostic test run, repeat testing by using the remaining purified nucleic acids or start from the original samples again.

## 10.2 Interpretation of Results

#### 10.2.1 Qualitative Analysis

Detection Channel		Parallé latamantation
FAM™	JOE™	- Result Interpretation
+	+*	HAV specific RNA detected.
-	+	No HAV specific RNA detected. Sample does not contain detectable amounts of HAV specific RNA.
-	-	RT-PCR inhibition or reagent failure. Repeat testing from original sample or collect and test a new sample.

<sup>\*</sup> Detection of the Internal Control in the JOE™ detection channel is not required for positive results in the FAM™ detection channel. A high HAV RNA load in the sample can lead to a reduced or absent Internal Control signal.

#### 11. Performance Evaluation

The analytical performance evaluation of the RealStar® HAV RT-PCR Kit 1.0 was done using the "1st WHO International Standard for hepatitis A RNA Nucleic Acid Amplification (NAT) Assays, NIBSC code: 00/560".

#### 11.1 Analytical Sensitivity

The analytical sensitivity (Limit of Detection: LoD) of the RealStar® HAV RT-PCR Kit 1.0 is defined as the concentration (IU per µI of the eluate) of HAV specific RNA molecules that can be detected with a positivity rate of 95%. The analytical sensitivity was determined by analysis of dilution series of quantified HAV RNA ("1st WHO International Standard for hepatitis A RNA Nucleic Acid Amplification (NAT) Assays, NIBSC code: 00/560").

Table 1: RT-PCR results used for the calculation of the analytical sensitivity with respect to the detection of HAV specific RNA

Input Conc. [IU/μΙ]	Number of Replicates	Number of Positives	Hit Rate [%]
10.000	12	12	100
3.162	12	12	100
1.000	12	12	100
0.316	24	22	92
0.200	12	6	50
0.100	24	11	46
0.060	12	3	25
0.032	12	0	0
0.010	12	0	0
0.003	12	0	0

The analytical sensitivity of the RealStar® HAV RT-PCR Kit 1.0 was determined by Probit analysis:

For the detection of HAV specific RNA, the analytical sensitivity is 0.46 IU/µI [95% confidence interval (CI): 0.31 - 0.98 IU/µI]

#### 11.2 Analytical Specificity

The analytical specificity of the RealStar® HAV RT-PCR Kit 1.0 is ensured by the thorough selection of the oligonucleotides (primers and probes). The oligonucleotides were checked by sequence comparison analysis against publicly available sequences to ensure that all relevant HAV genotypes will be detected.

The analytical specificity of the RealStar® HAV RT-PCR Kit 1.0 was evaluated by testing a panel of genomic RNA/DNA extracted from viruses related to HAV and other pathogens causing similar symptoms as HAV.

The RealStar® HAV RT-PCR Kit 1.0 did not cross-react with any of the following pathogens:

- Cytomegalovirus
- Echovirus 30
- Enterovirus 71
- Epstein-Barr virus
- Human adenovirus
- · Human herpesvirus 6A
- Human herpesvirus 6B
- Human herpesvirus 7
- Human herpesvirus 8

- · Herpes simplex virus 1
- · Herpes simplex virus 2
- Hepatitis B virus
- · Hepatitis C virus
- Hepatitis E virus
- Coxackievirus A3
- Rhinovirus 16
- Parechovirus 3
- Varicella-zoster virus

#### 11.3 Precision

Precision of the RealStar® HAV RT-PCR Kit 1.0 was determined as intra-assay variability (variability within one experiment), inter-assay variability (variability between different experiments) and inter-lot variability (variability between different production lots). Total variability was calculated by combining the three analysis.

The variability data are expressed in terms of standard deviation and coefficient of variation based on threshold cycle (C<sub>t</sub>) - values. At least six replicates per sample were analysed for intra-assay variability, inter-assay and inter-lot variability.

Table 2: Precision data for the detection of HAV specific RNA

HAV	Average Thresh- old Cycle (C <sub>,</sub> )	Standard Deviation	Coefficient of Variation [%]
Intra-Assay Variability	28.65	0.21	0.74
Inter-Assay Variability	28.66	0.15	0.53
Inter-Lot Variability	28.85	0.21	0.71
Total Variability	28.75	0.20	0.71

Table 3: Precision data for the detection of the Internal Control

Internal Control	Average Thresh- old Cycle (C <sub>,</sub> )	Standard Deviation	Coefficient of Variation [%]
Intra-Assay Variability	25.23	0.23	0.91
Inter-Assay Variability	25.26	0.19	0.73
Inter-Lot Variability	25.42	0.19	0.74
Total Variability	25.34	0.20	0.79

#### 12. Limitations

- Strict compliance with the instructions for use is required for optimal results.
- Use of this product is limited to personnel specially instructed and trained in the techniques of real-time PCR and in *in vitro* diagnostic procedures.
- Good laboratory practice is essential for proper performance of this assay.
  Extreme care should be taken to preserve the purity of the components of the kit and reaction setups. All reagents should be closely monitored for impurity and contamination. Any suspicious reagents should be discarded.
- Appropriate specimen collection, transport, storage and processing procedures are required for the optimal performance of this test.
- This assay must not be used on the specimen directly. Appropriate nucleic acid extraction methods have to be conducted prior to using this assay.
- The presence of RT-PCR inhibitors (e.g. heparin) may cause false negative or invalid results.
- Potential mutations within the target regions of the HAV genome covered by the primers and/or probes used in the kit may result in failure to detect the presence of the pathogen.
- As with any diagnostic test, results of the RealStar® HAV RT-PCR Kit 1.0 need to be interpreted in consideration of all clinical and laboratory findings.

## 13. Quality Control

In accordance with the altona Diagnostics GmbH EN ISO 13485-certified Quality Management System, each lot of RealStar® HAV RT-PCR Kit 1.0 is tested against predetermined specifications to ensure consistent product quality.

#### 14. Technical Assistance

For technical advice, please contact our Technical Support:

e-mail: support@altona-diagnostics.com

phone: +49-(0)40-5480676-0

#### 15. Literature

Versalovic, James, Carroll, Karen C., Funke, Guido, Jorgensen, James H., Landry, Marie Louise and David W. Warnock (ed). Manual of Clinical Microbiology. 10th Edition. ASM Press, 2011.

Cohen, Jonathan, Powderly, William G, and Steven M Opal. Infectious Diseases, Third Edition. Mosby, 2010.

#### 16. Trademarks and Disclaimers

RealStar® (altona Diagnostics); ABI Prism® (Applied Biosystems); ATCC® (American Type Culture Collection); CFX96™ (Bio-Rad); Cy® (GE Healthcare); FAM™, JOE™, ROX™ (Life Technologies); LightCycler® (Roche); Maxwell® (Promega); Mx 3005P™ (Stratagene); NucliSENS®, easyMag® (bioMérieux); Rotor-Gene®, QIAamp®, QIAsymphony® (QIAGEN); VERSANT® (Siemens Healthcare).

Registered names, trademarks, etc. used in this document, even if not specifically marked as such, are not to be considered unprotected by law.

The RealStar® HAV RT-PCR Kit 1.0 is a CE-marked diagnostic kit according to the European *in vitro* diagnostic directive 98/79/EC.

Product not licensed with Health Canada and not FDA cleared or approved.

Not available in all countries.

© 2017 altona Diagnostics GmbH; all rights reserved.

# 17. Explanation of Symbols

Notes:

IVD	In vitro diagnostic medical device
LOT	Batch code
CAP	Cap color
REF	Product number
CONT	Content
NUM	Number
COMP	Component
GTIN	Global trade identification number
<b>i</b>	Consult instructions for use
$\overline{\Sigma}$	Contains sufficient for "n" tests/reactions (rxns)
X	Temperature limit
$\subseteq$	Use-by date
	Manufacturer
<u> </u>	Caution
i	Note
$\square$	Version

always a drop ahead.

altona Diagnostics GmbH Mörkenstr. 12 22767 Hamburg, Germany

phone +49 40 548 0676 0 fax +49 40 548 0676 10

e-mail info@altona-diagnostics.com

www.altona-diagnostics.com